The estimated Net Worth of Peter Ordentlich is at least $420 Thousand dollars as of 15 February 2023. Peter Ordentlich owns over 25,000 units of Syndax Pharmaceuticals Inc stock worth over $319,281 and over the last 8 years he sold SNDX stock worth over $100,471. In addition, he makes $0 as Chief Scientific Officer at Syndax Pharmaceuticals Inc.
Sign up
Peter Ordentlich SNDX stock SEC Form 4 insiders trading
Peter has made over 8 trades of the Syndax Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of SNDX stock worth $173,750 on 15 February 2023.
The largest trade he's ever made was exercising 29,972 units of Syndax Pharmaceuticals Inc stock on 23 November 2020 worth over $92,314. On average, Peter trades about 9,150 units every 162 days since 2017. As of 15 February 2023 he still owns at least 17,428 units of Syndax Pharmaceuticals Inc stock.
You can see the complete history of Peter Ordentlich stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Ordentlich biography
Dr. Peter Ordentlich Ph.D. serves as Chief Scientific Officer of the Company. Dr. Ordentlich previously served as our Chief Technical Officer from November 2013 to August 2016, our Vice President, Translational Medicine from January 2012 to October 2013, our Executive Director, Translational Science from January 2011 to December 2011, and our Director, Scientific Affairs and Strategic Alliances from January 2008 to December 2010. Prior to founding the company, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies, a biological research non-profit organization. He also spent five years as a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company, which was acquired by Exelixis, Inc. Dr. Ordentlich received a B.A. in Biochemistry and a Ph.D. in Immunology from the University of Pennsylvania.
How old is Peter Ordentlich?
Peter Ordentlich is 51, he's been the Chief Scientific Officer of Syndax Pharmaceuticals Inc since 2016. There are 10 older and 7 younger executives at Syndax Pharmaceuticals Inc. The oldest executive at Syndax Pharmaceuticals Inc is Dr. Michael L. Meyers M.D., Ph.D., 70, who is the Chief Medical Officer & Sr. VP.
What's Peter Ordentlich's mailing address?
Peter's mailing address filed with the SEC is C/O SYNDAX PHARMACEUTICALS, INC., 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM, MA, 02451.
Insiders trading at Syndax Pharmaceuticals Inc
Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin, and Briggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.
What does Syndax Pharmaceuticals Inc do?
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
What does Syndax Pharmaceuticals Inc's logo look like?
Complete history of Peter Ordentlich stock trades at Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc executives and stock owners
Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Michael Metzger,
President, Chief Operating Officer, Director -
Briggs Morrison,
Chief Executive Officer, Director -
Dr. Briggs W. Morrison M.D.,
CEO & Director -
Michael A. Metzger M.B.A.,
Pres, COO & Director -
Michael Meyers,
Senior Vice President, Chief Medical Officer -
Dennis Podlesak,
Independent Chairman of the Board -
Pierre Legault,
Independent Director -
Keith Katkin,
Independent Director -
William Meury,
Independent Director -
Fabrice Egros,
Independent Director -
Jennifer Jarrett,
Independent Director -
Peter Ordentlich,
Chief Scientific Officer -
Luke Albrecht,
Senior Vice President, General Counsel, Secretary -
Daphne Karydas,
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer -
Dr. Edward A. Sausville M.D., Ph.D.,
Advisor -
Dr. Michael L. Meyers M.D., Ph.D.,
Chief Medical Officer & Sr. VP -
Luke J. Albrecht,
Sr. VP, Gen. Counsel & Sec. -
Alexander Nolte,
Interim Principal Financial Officer, VP & Chief Accounting Officer -
Dr. Michael Downes Ph.D.,
Co-Founder -
Dr. Ronald M. Evans Ph.D.,
Co-Founder, Advisor and Chair of Scientific Advisory Board -
Dr. Richard A. Heyman Ph.D.,
Co-Founder -
Dr. Peter Ordentlich B.Sc., Ph.D.,
Co-Founder & Chief Scientific Officer -
Martin H. Jr. Huber,
-
Neil Gallagher,
President, Head of R&D -
Luke Evnin,
Director -
Henry Chen,
-
Partners L P/Ilbiotechnolog...,
-
Steve M Sabus,
Chief Commercial Officer -
Ivor Royston,
Director -
Viii Associates, L.P.Blair ...,
-
Vi Associates, L.P.Blair Ja...,
-
Partners Vi, L.P.Blair Jame...,
-
George W. Jr. Sledge,
-
Bio Ventures Iv Qp Lp Scopa...,
-
Partners Viii, L.P.Blair Ja...,
-
Kim P. Kamdar,
Director -
Richard P Shea,
Chief Financial Officer -
Alexander Nolte,
Chief Accounting Officer -
Catherine Madigan,
Chief Medical Officer -
Keith A. Goldan,
Chief Financial Officer